Tumor markers reveal which HER2+ breast cancer patients may respond to less intensive chemotherapy

Дата публикации: 06-10-2026 19:20:01

The Journal of Clinical Oncology has published secondary results from the ECOG-ACRIN Cancer Research Group's CompassHER2-pCR clinical trial (EA1181, NCT04266249). The findings help identify which early-stage HER2-positive (HER2+) breast cancers may be most likely to respond to less intensive chemotherapy than the current standard.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	New study finds a blood test may detect recurring breast cancer faster than a scan	0	8.6	31-08-2026
2	Lumpectomy Margins and Local Recurrence in DCIS	0	8.55	01-09-2026
3	Low-risk prostate tumors reveal molecular signs linked to more aggressive cancer	0	8.18	07-10-2026
4	FLOT vs CROSS in Esophageal Adenocarcinoma	0	6.05	01-09-2026
5	ASTRO:	0	20.12	05-10-2026
6	DCIS Margins and Genomic Profiles—Refresh Not Rehash!	0	5.93	01-09-2026
7	ГК «ХимРар» запускает программу раннего доступа к терапии РМЖ инновационным препаратом биреоциклиб	0	9.4	30-09-2026
8	FDA approves combo therapy for breast cancer	0	11.84	18-09-2026
9	Signs of Breast Cancer Could Be Spotted 3-6 Years Before Diagnosis Using AI Screening, Shows Massive Study	0	6.18	14-06-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 14.44. Источник: medicalxpress.com.